Kathryn M. Ferguson, PhD

Dr. Ferguson’s research focuses on extracellular control of receptor tyrosine kinases (RTKs), aberrant activation of which can drive cancer and other diseases. Dr. Ferguson obtained her Ph.D. from Yale in 1996, and completed postdoctoral training at the University of Pennsylvania Perelman School of Medicine. She transitioned to an independent faculty position in the Department of Physiology at UPenn in 2003, returning to Connecticut in 2015 to join the Yale Cancer Biology Institute and Department of Pharmacology.